- Home
- RGC vs BCRX Comparison
RGC vs BCRX Comparison
Compare RGC & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RGC | BCRX |
|---|---|---|
| Founded | 2014 | 1986 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.5B |
| IPO Year | 2020 | 1995 |
Fundamental Metrics
Financial Performance| Metric | RGC | BCRX |
|---|---|---|
| Price | $5.85 | $8.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $20.82 |
| AVG Volume (30 Days) | 178.1K | ★ 3.0M |
| Earning Date | 10-31-2025 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 381.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $25,186,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.51 | $6.00 |
| 52 Week High | $69.00 | $11.22 |
Technical Indicators
Market Signals| Indicator | RGC | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.51 | 39.44 |
| Support Level | $4.71 | $8.79 |
| Resistance Level | $6.40 | $9.31 |
| Average True Range (ATR) | 0.56 | 0.30 |
| MACD | 0.22 | -0.08 |
| Stochastic Oscillator | 30.52 | 8.27 |
Price Performance
Historical ComparisonAbout RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.